Oculis Holding AG (ICE: OCS)

Market Cap	99.19B
Revenue (ttm)	138.64M
Net Income (ttm)	-11.12B
Shares Out	n/a
EPS (ttm)	-285.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,821
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	1,500.00 - 1,850.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 19, 2025

About Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneratio...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Riad Sherif
• Employees: 36
• Stock Exchange: Nasdaq Iceland
• Ticker Symbol: OCS

Financial Performance

In 2023, Oculis Holding AG's revenue was 883,000, a decrease of -3.18% compared to the previous year's 912,000. Losses were -88.80 million, 129.5% more than in 2022.

Financial numbers in CHF